Oncopeptides AB

Oncopeptides AB
About Us
Change country

Follow us:
Share:
Subscribe:

About Us

Oncopeptides is a global biotech company focused on the development of targeted therapies for difficult-to-treat hematological diseases. The company uses its proprietary peptide-drug conjugate (PDC) platform to develop compounds that rapidly and selectively deliver cytotoxic agents into cancer cells. The first drug coming from PDC platform, PEPAXTO®(melphalan flufenamide), has been launched in the U.S., for the treatment of adult patients with relapsed or refractory multiple myeloma. Melphalan flufenamide is evaluated in a comprehensive clinical study program including the global phase 3 studies OCEAN and LIGHTHOUSE. Oncopeptides is developing several new compounds based on the PDC platform. The first one is expected to enter into clinical development in 2021.Oncopeptides has approximately 300 coworkers. The global Headquarters is based in Stockholm, Sweden and the U.S. Headquarters is situated in Boston, Mass. The company is listed in the Mid Cap segment on Nasdaq Stockholm with the ticker ONCO. More information is available on www.oncopeptides.com.

Pick a time period -

Tags ( Active)

All Regulatory Non-Regulatory

INTERIM REPORT Q3 2019

Tue, Nov 19, 2019 08:00 CET

Summary Financial overview July 1 – September 30, 2019 · Net sales amounted to SEK 0.0 M (0.0) · Loss for the period was SEK 189.8 M (loss: 94.0) · Loss per share, before and after dilution, was SEK 3.53 (loss: 2.14) · On September 30 cash and cash equivalents amounted to SEK 1,122.3 M (488.9) Significant events during the period July 1 – September 30, 2019 · In late August it was announced that Klaas Bakker, MD, PhD, was appointed as Chief Medical Officer and assumed his duties in early November · In mid-September new interim data in RRMM patients with

There are no items matching the current filter

There are no more items matching the current filter

Share

About Us

INTERIM REPORT Q3 2019

Subscribe

Media